United States

Myovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Myovant Sciences Presents Additional Data on Relugolix Combination Therapy in Women with Uterine Fibroids and Ovulation Inhibition Study

Lead Product(s): Relugolix,Estradiol,Norethindrone Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: TAK-385

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 06, 2020

Details:

Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes in addition to improvement in hemoglobin levels in anemic women after administration of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg).

Daré Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Daré Bioscience Reports Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction

Lead Product(s): Ferrous Gluconate Anhydrous

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovaprene

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

Publication of a literature review article by Biology of Reproduction identifies and reviews 10 postcoital test studies of vaginal contraceptives involving 9 test products, including Daré’s Ovaprene, currently under a license agreement with Bayer.

Myovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Myovant Sciences Submits NDA to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids

Lead Product(s): Relugolix

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

NDA is supported by positive data from two Phase 3 studies and a long-term extension study, demonstrating sustained reduction in heavy menstrual bleeding while maintaining bone health through one year.

Myovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Myovant Sciences Provides Recent Updates From Phase 3 SPIRIT 2 and Phase 3 SPIRIT 1 study in women with endometriosis

Lead Product(s): Relugolix,Estradiol,Norethindrone Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

Co-primary endpoints and six key secondary endpoints met in Phase 3 SPIRIT 2 study in women with endometriosis, with results from the Phase 3 SPIRIT 1 study expected this year.

Evofem Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Evofem Biosciences Secures up to $25 Million in Convertible Note Financing

Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $25.0 million Upfront Cash: Undisclosed

Deal Type: Financing April 27, 2020

Details:

Funding to support the company's launch and commercialization plans for PHEXXI™.

Evofem Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Evofem Biosciences Announces Three New Phexxi™ or Presentation at 2020 ACOG

Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 24, 2020

Details:

Data demonstrate high efficacy rates of more than 93% when Phexxi is used as directed, also underscore the sexual satisfaction and lubricating factors experienced by women in the AMPOWER trial.

Myovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Myovant Sciences Gets 88% One-Year Response Rate with Relugolix

Lead Product(s): Relugolix

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

Details:

Primary efficacy endpoint met with 87.7% response rate at one year; women experienced, on average, an 89.9% reduction in menstrual blood loss

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Myovant Sciences

Myovant Sciences Presents Additional Data on Relugolix Combination Therapy in Women with Uterine Fibroids and Ovulation Inhibition Study

Daré Bioscience

Daré Bioscience Reports Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction

Myovant Sciences

Myovant Sciences Submits NDA to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids

Myovant Sciences

Myovant Sciences Provides Recent Updates From Phase 3 SPIRIT 2 and Phase 3 SPIRIT 1 study in women with endometriosis

Evofem Biosciences

Evofem Biosciences Secures up to $25 Million in Convertible Note Financing

Evofem Biosciences

Evofem Biosciences Announces Three New Phexxi™ or Presentation at 2020 ACOG

Myovant Sciences

Myovant Sciences Gets 88% One-Year Response Rate with Relugolix